CliffBio
small molecule

LUSEDRA

FOSPROPOFOL DISODIUM

Loss of exclusivity—loss of exclusivity
CompanyEisai →See this company's full patent-cliff portfolio

Drug detail

Brand nameLUSEDRA
Active ingredientFOSPROPOFOL DISODIUM
Strength1050MG/30ML (35MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2008
Marketing statusDISCN

More from Eisai

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LUSEDRA patent cliff — loss of exclusivity — | CliffBio